Chemomab Therapeutics Ltd - ADR CMMB

NAS: CMMB | ISIN: US16385C1045   17/05/2024
0,841 USD (-3,33%)
(-3,33%)   17/05/2024

7 maart 2024 · Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update · Persbericht

5 maart 2024 · Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference · Persbericht

20 februari 2024 · Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases · Persbericht

14 februari 2024 · Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update · Persbericht

5 februari 2024 · Chemomab Therapeutics to Participate in Upcoming Investor Conferences · Persbericht

30 januari 2024 · Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis · Persbericht

3 januari 2024 · Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024 · Persbericht

13 november 2023 · Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023 · Persbericht

9 november 2023 · Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update · Persbericht

6 november 2023 · Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement · Persbericht

30 oktober 2023 · Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update · Persbericht

26 oktober 2023 · Chemomab Therapeutics to Present at Upcoming Scientific Conferences · Persbericht

28 september 2023 · Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities Conference · Persbericht

29 augustus 2023 · Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference · Persbericht

14 augustus 2023 · Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update · Persbericht

28 juni 2023 · Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis · Persbericht

26 juni 2023 · Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023 · Persbericht

21 juni 2023 · Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 · Persbericht

5 juni 2023 · Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update · Persbericht

2 juni 2023 · Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis · Persbericht

Mijn selecties